- Home
- TACH vs CRVS Comparison
TACH vs CRVS Comparison
Compare TACH & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TACH
- CRVS
- Stock Information
- Founded
- TACH 2024
- CRVS 2014
- Country
- TACH United States
- CRVS United States
- Employees
- TACH N/A
- CRVS 31
- Industry
- TACH
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- TACH
- CRVS Health Care
- Exchange
- TACH Nasdaq
- CRVS Nasdaq
- Market Cap
- TACH 345.7M
- CRVS 328.5M
- IPO Year
- TACH 2025
- CRVS 2016
- Fundamental
- Price
- TACH $10.10
- CRVS $3.92
- Analyst Decision
- TACH
- CRVS Strong Buy
- Analyst Count
- TACH 0
- CRVS 4
- Target Price
- TACH N/A
- CRVS $15.00
- AVG Volume (30 Days)
- TACH 32.9K
- CRVS 786.0K
- Earning Date
- TACH 01-01-0001
- CRVS 08-05-2025
- Dividend Yield
- TACH N/A
- CRVS N/A
- EPS Growth
- TACH N/A
- CRVS N/A
- EPS
- TACH N/A
- CRVS N/A
- Revenue
- TACH N/A
- CRVS N/A
- Revenue This Year
- TACH N/A
- CRVS N/A
- Revenue Next Year
- TACH N/A
- CRVS N/A
- P/E Ratio
- TACH N/A
- CRVS N/A
- Revenue Growth
- TACH N/A
- CRVS N/A
- 52 Week Low
- TACH $9.51
- CRVS $1.75
- 52 Week High
- TACH $10.48
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- TACH N/A
- CRVS 49.54
- Support Level
- TACH N/A
- CRVS $3.83
- Resistance Level
- TACH N/A
- CRVS $4.33
- Average True Range (ATR)
- TACH 0.00
- CRVS 0.28
- MACD
- TACH 0.00
- CRVS -0.03
- Stochastic Oscillator
- TACH 0.00
- CRVS 21.74
About TACH Titan Acquisition Corp. Class A Ordinary Shares
Titan Acquisition Corp is a blank check company.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).